BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Contract Manufacturing

CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth

New research from the CPHI Annual Report 2022 – launched during CPHI Frankfurt (1-3 November, 2022) – predicts that huge volumes of V...

October 28, 2022 | News

Samsung Biologics Reports Third Quarter 2022 Financial Results

Recorded consolidated revenue of KRW 873 billion in Q3'22 Recorded consolidated operating profit of KRW 324.7 billion in Q3'...

October 27, 2022 | News

WuXi Biologics Announces GMP Release of 48,000L Commercial Drug Substance Manufacturing Facility in Hebei, China

The facility's design incorporates environmental protection, energy conservation, emission reduction, and resource utilization – a reflection of WuXi...

October 26, 2022 | News

WuXi Biologics adds further capacity and capability for drug product fill & finish

WuXi Biologics to provide global customers with end-to-end integrated solutions for diversified modalities, including mRNA-LNP. WuXi Biologics ("WuXi Bio"...

October 24, 2022 | News

CPHI Annual Report predicts growth for biologics manufacturing and CMOs in 2023

CPHI Frankfurt Report predicts ‘biologics outsourcing to surge in 2023, as China’s innovation engine stalls’ Ahead of the world’s ...

October 21, 2022 | News

GenScript ProBio Signs MOU to Form Strategic Partnership with GeneCraft

GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and GeneCraft (Suk Chul Bae, CEO), a global research team led by Professor Suk Ch...

October 18, 2022 | News

Samsung Biologics obtains three global ISO certifications

Receives accreditation for information security management system, information security in cloud services, and anti-bribery management systems F...

October 14, 2022 | News

Samsung Biologics unlocks additional capacity for production at its newest Plant 4

Plant 4 commences GMP operations within just 23 months since groundbreaking, as planned Partial operations add fresh biomanufacturing capacity of 60,000...

October 12, 2022 | News

WuXi Biologics and Toregem BioPharma Sign MOU for Development of Anti-USAG-1 Antibody

Within the partnership, Toregem BioPharma will have access to WuXi Biologics' integrated CMC services in cell line development, cell banking and testing se...

October 12, 2022 | News

Vetter drives its sustainability campaign forward

Repeat participation in Baden Wuerttemberg’s Sustainability Days Greater inclusion of employees due to involvement in various initiatives Awards ...

October 11, 2022 | News

Merck Boosts Commercial Capacity in France as Part of New Millipore® CTDMO Services

New 2,700-square-meter facility expands production capacity for monoclonal antibodies (mAbs) and other recombinant proteins Clients benefit from differe...

October 05, 2022 | News

Samsung Biologics introduces new development platforms S-DUAL™ and DEVELOPICK™

Two distinctive platforms will streamline the antibody development process. With an advanced design and high binding affinity, S-DUAL™ ensures opt...

September 30, 2022 | News

WuXi Biologics Topped Off the Steel on its Commercial Biomanufacturing Facility

WuXi Biologics ("WuXi Bio") (2269.HK), a global Contract Research, Development and Manufacturing Organization (CRDMO), held a topping-off ceremony, i...

September 29, 2022 | News

WuXi STA Opens First High Potency Oral Drug Product Manufacturing Facility

WuXi STA, a leading global Contract Research Development and Manufacturing Organization (CRDMO), today announced the opening of its first high potency (HP)...

September 27, 2022 | News

Stay Connected